Possible Precipitation of Migraine Attacks with Prophylactic Treatment

The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine suf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European neurology 2009-01, Vol.61 (1), p.23-26
Hauptverfasser: Donnet, A., Vuillaume De Diego, E., Lanteri-Minet, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 26
container_issue 1
container_start_page 23
container_title European neurology
container_volume 61
creator Donnet, A.
Vuillaume De Diego, E.
Lanteri-Minet, M.
description The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.
doi_str_mv 10.1159/000165345
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20911669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1619147891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</originalsourceid><addsrcrecordid>eNpd0E1LAzEQBuAgiq3Vg3eRxYPgYTWT7ObjWIpVoWIP9bykabZNu18mKdJ_b6TFgqdhhmeG4UXoGvAjQC6fMMbAcprlJ6gPGYFUSqCnqB_HWUoxIT104f06trnk4hz1QMhMMMn6aDxtvbfzyiRTZ7TtbFDBtk3Slsm7XTplG5MMQ1B645NvG1aRtd1qVykdrE5mzqhQmyZcorNSVd5cHeoAfY6fZ6PXdPLx8jYaTlJNGQlpDgyDWGREU06l4TkFOudUc82E4CB4yfWCKJUzDmWZCWMWJZlzJkuttcKUDtD9_m7n2q-t8aGordemqlRj2q0vCJYAjMkI7_7Bdbt1TfytAJlJEEBZRA97pF1MwZmy6JytldsVgIvfZIu_ZKO9PRzczmuzOMpDlBHc7MFGuaVxR7Df_wHYensf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>194918136</pqid></control><display><type>article</type><title>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</title><source>MEDLINE</source><source>Karger_医学期刊</source><source>Alma/SFX Local Collection</source><creator>Donnet, A. ; Vuillaume De Diego, E. ; Lanteri-Minet, M.</creator><creatorcontrib>Donnet, A. ; Vuillaume De Diego, E. ; Lanteri-Minet, M.</creatorcontrib><description>The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.</description><identifier>ISSN: 0014-3022</identifier><identifier>EISSN: 1421-9913</identifier><identifier>DOI: 10.1159/000165345</identifier><identifier>PMID: 18948696</identifier><identifier>CODEN: EUNEAP</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adrenergic beta-Antagonists - adverse effects ; Adult ; Aged ; Anticonvulsants - adverse effects ; Antidepressive Agents - adverse effects ; Calcium Channel Blockers - adverse effects ; Ergotamine - adverse effects ; Female ; Humans ; Male ; Middle Aged ; Migraine Disorders - chemically induced ; Migraine Disorders - prevention &amp; control ; Original Paper ; Serotonin Antagonists - adverse effects</subject><ispartof>European neurology, 2009-01, Vol.61 (1), p.23-26</ispartof><rights>2008 S. Karger AG, Basel</rights><rights>2008 S. Karger AG, Basel.</rights><rights>Copyright (c) 2008 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</citedby><cites>FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18948696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Donnet, A.</creatorcontrib><creatorcontrib>Vuillaume De Diego, E.</creatorcontrib><creatorcontrib>Lanteri-Minet, M.</creatorcontrib><title>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</title><title>European neurology</title><addtitle>Eur Neurol</addtitle><description>The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.</description><subject>Adrenergic beta-Antagonists - adverse effects</subject><subject>Adult</subject><subject>Aged</subject><subject>Anticonvulsants - adverse effects</subject><subject>Antidepressive Agents - adverse effects</subject><subject>Calcium Channel Blockers - adverse effects</subject><subject>Ergotamine - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Migraine Disorders - chemically induced</subject><subject>Migraine Disorders - prevention &amp; control</subject><subject>Original Paper</subject><subject>Serotonin Antagonists - adverse effects</subject><issn>0014-3022</issn><issn>1421-9913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0E1LAzEQBuAgiq3Vg3eRxYPgYTWT7ObjWIpVoWIP9bykabZNu18mKdJ_b6TFgqdhhmeG4UXoGvAjQC6fMMbAcprlJ6gPGYFUSqCnqB_HWUoxIT104f06trnk4hz1QMhMMMn6aDxtvbfzyiRTZ7TtbFDBtk3Slsm7XTplG5MMQ1B645NvG1aRtd1qVykdrE5mzqhQmyZcorNSVd5cHeoAfY6fZ6PXdPLx8jYaTlJNGQlpDgyDWGREU06l4TkFOudUc82E4CB4yfWCKJUzDmWZCWMWJZlzJkuttcKUDtD9_m7n2q-t8aGordemqlRj2q0vCJYAjMkI7_7Bdbt1TfytAJlJEEBZRA97pF1MwZmy6JytldsVgIvfZIu_ZKO9PRzczmuzOMpDlBHc7MFGuaVxR7Df_wHYensf</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Donnet, A.</creator><creator>Vuillaume De Diego, E.</creator><creator>Lanteri-Minet, M.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20090101</creationdate><title>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</title><author>Donnet, A. ; Vuillaume De Diego, E. ; Lanteri-Minet, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-516018d42c3739e75313b73c7c6887187f7cd2aa5671ff48eedf2b769fccca033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adrenergic beta-Antagonists - adverse effects</topic><topic>Adult</topic><topic>Aged</topic><topic>Anticonvulsants - adverse effects</topic><topic>Antidepressive Agents - adverse effects</topic><topic>Calcium Channel Blockers - adverse effects</topic><topic>Ergotamine - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Migraine Disorders - chemically induced</topic><topic>Migraine Disorders - prevention &amp; control</topic><topic>Original Paper</topic><topic>Serotonin Antagonists - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Donnet, A.</creatorcontrib><creatorcontrib>Vuillaume De Diego, E.</creatorcontrib><creatorcontrib>Lanteri-Minet, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>Science Database (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>European neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Donnet, A.</au><au>Vuillaume De Diego, E.</au><au>Lanteri-Minet, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Possible Precipitation of Migraine Attacks with Prophylactic Treatment</atitle><jtitle>European neurology</jtitle><addtitle>Eur Neurol</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>61</volume><issue>1</issue><spage>23</spage><epage>26</epage><pages>23-26</pages><issn>0014-3022</issn><eissn>1421-9913</eissn><coden>EUNEAP</coden><abstract>The initiation of a prophylactic treatment in a migraine sufferer depends upon the stratification of the patient’s frequency of attacks and the disability they cause, as well as the patient’s acute consumption and comorbid diseases. We report on 14 patients who were among a group of 618 migraine sufferers who received a new preventative treatment. These 14 patients developed an increase in the frequency of their migraine attacks that was possibly induced by this new prophylactic treatment. The clinical description of the migraine attacks remained the same but the frequency of the attacks of migraine without aura was dramatically increased. This is, to our knowledge, the first description of a possible precipitation of attacks of migraine without aura with a prophylactic treatment. There is no link with a specific class of prophylactic treatment. We hypothesize that the migraine sufferers who experienced aggravation after the new prophylactic drug had been introduced had a paradoxical decrease in the induction threshold for cortical spreading depression (CSD). Mechanisms of such a decrease are unknown and are probably multifactorial, but changes in serotonin neurotransmission have been experimentally demonstrated to modify cortical excitability and favour CSD. The aggravation was described only for attacks without aura. However, with only 14 patients, it is not possible to predict whether suffering from that the type of migraine is a factor that predisposes a patient to aggravation. While additional cases are necessary, physicians should be aware of the possibility that prophylactic treatment may exacerbate migraine attacks.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>18948696</pmid><doi>10.1159/000165345</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-3022
ispartof European neurology, 2009-01, Vol.61 (1), p.23-26
issn 0014-3022
1421-9913
language eng
recordid cdi_proquest_miscellaneous_20911669
source MEDLINE; Karger_医学期刊; Alma/SFX Local Collection
subjects Adrenergic beta-Antagonists - adverse effects
Adult
Aged
Anticonvulsants - adverse effects
Antidepressive Agents - adverse effects
Calcium Channel Blockers - adverse effects
Ergotamine - adverse effects
Female
Humans
Male
Middle Aged
Migraine Disorders - chemically induced
Migraine Disorders - prevention & control
Original Paper
Serotonin Antagonists - adverse effects
title Possible Precipitation of Migraine Attacks with Prophylactic Treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A11%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Possible%20Precipitation%20of%20Migraine%20Attacks%20with%20Prophylactic%20Treatment&rft.jtitle=European%20neurology&rft.au=Donnet,%20A.&rft.date=2009-01-01&rft.volume=61&rft.issue=1&rft.spage=23&rft.epage=26&rft.pages=23-26&rft.issn=0014-3022&rft.eissn=1421-9913&rft.coden=EUNEAP&rft_id=info:doi/10.1159/000165345&rft_dat=%3Cproquest_cross%3E1619147891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=194918136&rft_id=info:pmid/18948696&rfr_iscdi=true